Ozempic Wars | The Next Injection | 2

What It Covers

Eli Lilly challenges Novo Nordisk's dominance in the GLP-1 weight loss drug market with Zepbound, which shows 20% weight loss versus Wegovy's 13%, triggering pricing wars, supply shortages, and leadership upheaval at both pharmaceutical giants.

Key Questions Answered

• •Direct-to-consumer strategy: Eli Lilly launched LillyDirect in January 2024, enabling virtual prescriber consultations and home delivery, then cut Zepbound prices from $1,000 to $500 monthly by selling vials instead of pre-loaded shots, projecting 30% revenue increase to $45 billion annually.
• •Dual-action mechanism advantage: Zepbound's tirzepatide mimics both GLP-1 and GIP hormones, processing sugar and fat more efficiently than Wegovy's single-hormone semaglutide, delivering 7 percentage points higher weight loss and capturing 58% of the US GLP-1 market by late 2024.
• •Political narrative control: Senator Bernie Sanders publicly challenged Novo Nordisk's CEO with written PBM commitments proving lower prices wouldn't restrict coverage, demonstrating how unprepared corporate explanations lose to simple political messaging in regulated industries, causing stock damage and forcing price reductions.
• •Partnership risk calculation: Novo Nordisk partnered with telehealth disruptor Hims and Hers in April 2025 at $599 monthly, then terminated the relationship two months later over continued compounded drug sales, showing how co-opting competitors can backfire when brand control is surrendered.